Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.

(2020) Masatoshi Kudo et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

(2020) Shukui Qin et al.   LANCET ONCOLOGY

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

(2020) Feng Bi et al.   JOURNAL OF CLINICAL ONCOLOGY

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

(2020) Qiu Li et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

(2020) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).

(2019) Yung-Jue Bang et al.   JOURNAL OF CLINICAL ONCOLOGY

Camrelizumab: First Global Approval

(2019) Anthony Markham et al.   DRUGS

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

(2018) Hongnan Mo et al.   BRITISH JOURNAL OF CANCER

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

(2018) Dai Fukumura et al.   Nature Reviews Clinical Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment

(2018) S K Qin et al.   ANNALS OF ONCOLOGY

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

(2018) Jianming Xu et al.   CLINICAL CANCER RESEARCH

Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma

(2018) Xinlei Gong et al.   HEPATOBILIARY SURGERY AND NUTRITION

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma

(2016) Tai Hato et al.   Immunotherapy

Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)

(2015) Claudia Allemani et al.   LANCET

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

(2013) Shukui Qin et al.   JOURNAL OF CLINICAL ONCOLOGY